Thyromimetic drugs are synthetic agonists of the thyroid hormone receptor's isoforms TR α1, TRα2, TRβ1, or TRβ2, mimicking some or all of the effects of endogenously produced thyroid hormones that regulate metabolism.[1][2] Some thyromimetic drugs are selective for various of these receptors over others, enabling more targeted effects and reducing toxicity. Thyromimetics selective for TRβ—including eprotirome,[3] sobetirome,[4] resmetirom,[5] and the prodrug VK2809—have been investigated for the treatment of non-alcoholic fatty liver disease, dyslipidemia, and other metabolic and neurodegenerative diseases.[3]

References

edit
  1. ^ Unnikrishnan, A. G.; Baruah, Manash; Kalra, Sanjay (December 2012). "Thyromimetics: What does the future hold?". Indian Journal of Endocrinology and Metabolism. 16 (Suppl 2): S159–S161. doi:10.4103/2230-8210.104029. ISSN 2230-8210. PMC 3603016. PMID 23565368.
  2. ^ Devereaux, Jordan; Ferrara, Skylar J.; Scanlan, Thomas S. (2018). "Quantification of Thyromimetic Sobetirome Concentration in Biological Tissue Samples". Thyroid Hormone Nuclear Receptor. Methods in Molecular Biology. Vol. 1801. Springer. pp. 193–206. doi:10.1007/978-1-4939-7902-8_16. ISBN 978-1-4939-7901-1.
  3. ^ a b Saponaro, Federica; Sestito, Simona; Runfola, Massimiliano; Rapposelli, Simona; Chiellini, Grazia (2020). "Selective Thyroid Hormone Receptor-Beta (TRβ) Agonists: New Perspectives for the Treatment of Metabolic and Neurodegenerative Disorders". Frontiers in Medicine. 7: 331. doi:10.3389/fmed.2020.00331. ISSN 2296-858X. PMC 7363807. PMID 32733906.
  4. ^ Tancevski, Ivan; Demetz, Egon; Eller, Philipp (1 January 2011). "Sobetirome: A Selective Thyromimetic for the Treatment of Dyslipidemia". Recent Patents on Cardiovascular Drug Discovery. 6 (1): 16–19. doi:10.2174/157489011794578473.
  5. ^ Alkhouri, Naim (1 February 2020). "Thyromimetics as emerging therapeutic agents for nonalcoholic steatohepatitis: rationale for the development of resmetirom (MGL-3196)". Expert Opinion on Investigational Drugs. 29 (2): 99–101. doi:10.1080/13543784.2020.1708899. ISSN 1354-3784.

Further reading

edit

📚 Artikel Terkait di Wikipedia

Sobetirome

Sobetirome (GC-1) is a thyromimetic drug that binds to the thyroid hormone receptor TRβ1 preferentially compared to TRα1. It has been investigated for

VK2809

VK2809 (formerly known as MB07811) is a thyromimetic prodrug whose active form is selective for the THR-β isoform. It is being developed by Viking Therapeutics

Elunetirom

stage of development for multiple sclerosis and adrenomyeloneuropathy. Thyromimetic List of investigational antidepressants List of investigational bipolar

TERN-501

TERN-501 is a selective thyromimetic drug that is being developed for the treatment of non-alcoholic fatty liver disease. Finan, Brian; Parlee, Sebastian

Levothyroxine

Liotrix Thyroxine Tiratricol (TRIAC) Triiodothyronine Thyroid extract Thyromimetics (selective agonists) Elunetirom (ABX-002, MA-JD21) Eprotirome (KB-2115)

Omzotirome

Omzotirome (INN), formerly codenamed TRC-150094, is a thyromimetic drug which acts as a metabolic modulator which restores metabolic flexibility. It has

Iodine

Liotrix Thyroxine Tiratricol (TRIAC) Triiodothyronine Thyroid extract Thyromimetics (selective agonists) Elunetirom (ABX-002, MA-JD21) Eprotirome (KB-2115)

Propranolol

Liotrix Thyroxine Tiratricol (TRIAC) Triiodothyronine Thyroid extract Thyromimetics (selective agonists) Elunetirom (ABX-002, MA-JD21) Eprotirome (KB-2115)